Degarelix Gets a Trade Name: Firmagon
FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer.
Print Issue: September 01, 2009
‘Smart Bomb’ Delivers Prostate Cancer Drug
Adding a tyrosine ring to a chemotherapy agent creates a targeted imaging tool with therapeutic effects.
Adenovirus/PSA Vaccine Shows Promise
Researchers observe positive T cell responses in men with nonmetastatic recurrence prostate cancer.
Electronic Diaries for Diabetes Monitoring Improve Adherence
NEW ORLEANS—Diabetic patients appear to be proficient at using a mobile, handheld electronic diary that enables effective remote patient monitoring during intensive insulin titration.
Erectile Dysfunction in Diabetics Frequently Neglected
More than half of the men attending a diabetes clinic were not asked about erectile dysfunction.
Urologic Cancers Rise in Denmark
The overall incidences of kidney, bladder, pelvis, and ureter cancers in Denmark increased in both sexes from 1944 to 2003, Danish investigators reported in Urology (2009; published online ahead of print).
Nerve Stimulation An Overactive Bladder Option
Percutaneous tibial nerve stimulation may be considered an alternative treatment for overactive bladder (OAB), researchers reported in the Journal of Urology (2009;182:1055-1061).
Finasteride Use by Men With BPH Cuts PCa Risk
Finasteride treatment reduces the risk of low-grade prostate cancer (PCa) in men taking the drug for symptomatic benign prostatic hyperplasia (BPH), data show.
UACR, eGFR Predict Diabetics’ Outcomes
These two values are independently associated with the likelihood of cardiovascular and renal events.
U.S. vs. Canada: Doctors Give Their View
Canada provides coverage for all citizens through a single-payer system, but does quality suffer?
- Loading...
Loading...
Loading... 
Loading...